Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Stellar Pharmaceuticals Inc (SLXCF) since 2010 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Stellar Pharmaceuticals Inc. Table 2 shows the detailed insider transactions. This company's CIK number is 1159019.
Total stock buying since 2010: $3,085,794.
Total stock sales since 2010: $71,324.
Total stock option exercises since 2010: $0.
▪ Recent SEC 13D filings for all companies
▪ Recent portfolio reports of all companies
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2013 | 8,437,500 | $1,375,000 | 0 | $0 | 0 | $0 |
| 2012 | 3,125,000 | $1,638,631 | 0 | $0 | 0 | $0 |
| 2011 | 116,355 | $72,163 | 101,165 | $51,477 | 0 | $0 |
| 2010 | 0 | $0 | 22,065 | $19,847 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2013-03 | 5,000,000 | $0 | 0 | $0 | 0 | $0 |
| 2013-02 | 3,437,500 | $1,375,000 | 0 | $0 | 0 | $0 |
| 2012-11 | 100,000 | $35,000 | 0 | $0 | 0 | $0 |
| 2012-09 | 130,000 | $64,831 | 0 | $0 | 0 | $0 |
| 2012-08 | 895,000 | $418,800 | 0 | $0 | 0 | $0 |
| 2012-03 | 2,000,000 | $1,120,000 | 0 | $0 | 0 | $0 |
| 2011-11 | 0 | $0 | 71,575 | $37,787 | 0 | $0 |
| 2011-10 | 0 | $0 | 29,590 | $13,690 | 0 | $0 |
| 2011-07 | 12,620 | $7,824 | 0 | $0 | 0 | $0 |
| 2011-04 | 103,735 | $64,339 | 0 | $0 | 0 | $0 |
| 2010-08 | 0 | $0 | 265 | $227 | 0 | $0 |
| 2010-06 | 0 | $0 | 21,800 | $19,620 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2013-03-04 | Gregory James M | Buy | 2,500,000 | .00 | 0 |
| 2013-03-04 | Gregory John M | Buy | 2,500,000 | .00 | 0 |
| 2013-02-27 | Harris Robert Paul (Chief Executive Officer) | Buy | 625,000 | .40 | 250,000 |
| 2013-02-27 | Elora Financial Management Inc. (CFO) | Buy | 62,500 | .40 | 25,000 |
| 2013-02-27 | Goldman Steven Harold (Director) | Buy | 1,250,000 | .40 | 500,000 |
| 2013-02-27 | Thrasher Francis Martin (Director) | Buy | 1,250,000 | .40 | 500,000 |
| 2013-02-27 | Tenney Arnold (Chairman) | Buy | 250,000 | .40 | 100,000 |
| 2012-11-19 | Goldman Steven Harold (Director) | Buy | 100,000 | .35 | 35,000 |
| 2012-09-07 | Goldman Steven Harold (Director) | Buy | 25,000 | .50 | 12,500 |
| 2012-09-05 | Goldman Steven Harold (Director) | Buy | 84,500 | .50 | 42,081 |
| 2012-09-04 | Goldman Steven Harold (Director) | Buy | 20,500 | .50 | 10,250 |
| 2012-08-31 | Goldman Steven Harold (Director) | Buy | 35,000 | .48 | 16,800 |
| 2012-08-27 | Goldman Steven Harold (Director) | Buy | 40,000 | .38 | 15,200 |
| 2012-08-27 | Tenney Arnold (Chairman) | Buy | 20,000 | .38 | 7,600 |
| 2012-08-27 | Palmer Susan | Buy | 400,000 | .47 | 189,600 |
| 2012-08-27 | Gregory John M | Buy | 400,000 | .47 | 189,600 |
| 2012-03-22 | Harris Robert Paul (Chief Executive Officer) | Buy | 1,100,000 | .56 | 616,000 |
| 2012-03-22 | Elora Financial Management Inc. (CFO) | Buy | 900,000 | .56 | 504,000 |
| 2011-11-29 | Riehl Peter Roy (10% Owner) | Sale | 25,000 | .55 | 13,750 |
| 2011-11-28 | Riehl Peter Roy (10% Owner) | Sale | 25,000 | .53 | 13,250 |
| 2011-11-15 | Riehl Peter Roy (10% Owner) | Sale | 14,275 | .50 | 7,137 |
| 2011-11-09 | Riehl Peter Roy (10% Owner) | Sale | 7,300 | .50 | 3,650 |
| 2011-10-20 | Riehl Peter Roy (10% Owner) | Sale | 9,590 | .51 | 4,890 |
| 2011-10-18 | Riehl Peter Roy (10% Owner) | Sale | 20,000 | .44 | 8,800 |
| 2011-07-20 | Riehl Peter Roy (10% Owner) | Buy | 12,620 | .62 | 7,824 |
| 2011-04-21 | Riehl Peter Roy (10% Owner) | Buy | 13,735 | .72 | 9,889 |
| 2011-04-12 | Riehl Peter Roy (10% Owner) | Buy | 50,000 | .69 | 34,250 |
| 2011-04-05 | Riehl Peter Roy (10% Owner) | Buy | 40,000 | .51 | 20,200 |
| 2010-08-26 | Goldman Steven Harold (Director) | Sale | 265 | .86 | 227 |
| 2010-06-30 | Clarke Janice Marie (Chief Financial Officer) | Sale | 21,800 | .90 | 19,620 |
Insider trading activities including stock purchases, stock sales, and option exercises of SLXCF listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Stellar Pharmaceuticals Inc (symbol SLXCF, CIK number 1159019) see the Securities and Exchange Commission (SEC) website.